Literature DB >> 26303594

Decade in review-bone: Great strides made but still further to go.

Ian R Reid1.   

Abstract

Mesh：

Year:  2015        PMID： 26303594     DOI： 10.1038/nrendo.2015.143

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Authors:  Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272

2.  Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

Authors:  Ian R Reid; Paul Miller; Kenneth Lyles; William Fraser; Jacques P Brown; Youssef Saidi; Peter Mesenbrink; Guoqin Su; Judy Pak; Ken Zelenakas; Monica Luchi; Peter Richardson; David Hosking
Journal:  N Engl J Med       Date:  2005-09-01       Impact factor: 91.245

3.  Romosozumab in postmenopausal women with low bone mineral density.

Authors:  Michael R McClung; Andreas Grauer; Steven Boonen; Michael A Bolognese; Jacques P Brown; Adolfo Diez-Perez; Bente L Langdahl; Jean-Yves Reginster; Jose R Zanchetta; Scott M Wasserman; Leonid Katz; Judy Maddox; Yu-Ching Yang; Cesar Libanati; Henry G Bone
Journal:  N Engl J Med       Date:  2014-01-01       Impact factor: 91.245

4.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

5.  Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Authors:  Itaru Urakawa; Yuji Yamazaki; Takashi Shimada; Kousuke Iijima; Hisashi Hasegawa; Katsuya Okawa; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Nature       Date:  2006-10-29       Impact factor: 49.962

6.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

7.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

8.  Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.

Authors:  Alexander G Robling; Paul J Niziolek; Lee A Baldridge; Keith W Condon; Matthew R Allen; Imranul Alam; Sara M Mantila; Jelica Gluhak-Heinrich; Teresita M Bellido; Stephen E Harris; Charles H Turner
Journal:  J Biol Chem       Date:  2007-12-17       Impact factor: 5.157

Review 9.  Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis.

Authors:  Mark J Bolland; Andrew Grey; Alison Avenell; Greg D Gamble; Ian R Reid
Journal:  BMJ       Date:  2011-04-19

10.  Zoledronic acid and clinical fractures and mortality after hip fracture.

Authors:  Kenneth W Lyles; Cathleen S Colón-Emeric; Jay S Magaziner; Jonathan D Adachi; Carl F Pieper; Carlos Mautalen; Lars Hyldstrup; Chris Recknor; Lars Nordsletten; Kathy A Moore; Catherine Lavecchia; Jie Zhang; Peter Mesenbrink; Patricia K Hodgson; Ken Abrams; John J Orloff; Zebulun Horowitz; Erik Fink Eriksen; Steven Boonen
Journal:  N Engl J Med       Date:  2007-09-17       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.